Tagged with R

USA Dr Peter Marks MD, PhD, director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), highlights the Center’s contributions related to the regulatory science behind vaccine development, including vaccines to prevent COVID-19; the Center’s efforts to facilitate the advancement of the field…

Switzerland Interpharma CEO Dr René P Buholzer outlines the holistic strategy that needs to be put in place to maintain Switzerland’s leading position in innovation, market access and reimbursement challenges for new medicines, and why an open, globalised Europe is key for security of supply.   The challenge for the future…

Roundup The latest news from Asia-Pacific pharma, including Alovtech and DKSH’s biosimilar commercialisation partnership, Samsung Biologics and AstraZeneca’s joint move to strengthen their manufacturing collaborations, and whether President Duterte’s vaccine diplomacy can kickstart the domestic Filipino pharma industry.   Alvotech and DKSH have expanded their partnership to commercialize six new biosimilar…

Europe Ole Olesen, executive director of the European Vaccine Initiative (EVI), shares the highlights of his first nine months in the job grappling with a global pandemic; the mission of EVI to support the development of non-commercially viable vaccines as well as to create a European vaccine infrastructure; as well as…

USA Regular PharmaBoardroom contributor Brendan Shaw weighs in on the potential implications for US pharma of President Donald Trump’s latest executive order on medicine pricing, its wider impact on other high income economies, and why a Democratic victory in the upcoming presidential election will not see this issue go away.  …

Opinion Robert Hall of Ardent Search, an executive search boutique specialised in the life sciences and healthcare sectors, highlights the five key points for recruiters and pharma companies to consider when hiring market access professionals to work in Asia.   Whether it is an established or a developing market, access is…

USA As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM) president & CEO Chip Davis; Carol Lynch, president of Sandoz US, head of Sandoz North America and member of the Sandoz Executive Committee; and Amgen’s biosimilars business…

Roundup Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology collaboration with AbbVie, Jiangsu Hengrui’s latest deal with US biotech Dyadic, and Fosun Pharma’s role in the Pfizer/BioNTech COVID-19 vaccine.   AbbVie and Chinese biotech I-Mab Enter Into Global Strategic Partnership…

Gilead With remdesivir practically a household name today as the first therapeutic to be approved for the treatment of COVID-19 patients, Gilead chairman and CEO Daniel O’Day and Gilead vice-president and general manager of the Asia 5 region (Singapore, South Korea, Hong Kong, Taiwan, Malaysia) Andrew Hexter are determined to stress…

Norway Photo: Sofia Linden / Oslo Cancer Cluster Oncologist Jon Amund Kyte shares some of the groundbreaking immunotherapy research that he and his team is conducting at Oslo University Hospital. Kyte also explores how Norway can better develop its clinical footprint and what his hopes for the future of experimental cancer…

Switzerland In a wide-ranging conversation, Martin Naville of AmCham Switzerland looks at the evolution of the Switzerland-US trade relationship and the importance of pharma within it, the pressing need for a free trade agreement between the two countries, and why Switzerland needs to “wake up” to remain globally competitive.   In…

Norway Anette Margrethe Storstein MD PhD of the Norwegian Brain Council introduces the burden of neurodegenerative disease in Norway today, the ongoing impact of the country’s National Brain Plan, and Norway’s untapped potential in neuroscience R&D.   Norway has unfulfilled innovation potential. There is a lot to be gained from an…